» Articles » PMID: 25900242

Differential Expression of Cell Cycle Regulators in CDK5-dependent Medullary Thyroid Carcinoma Tumorigenesis

Overview
Journal Oncotarget
Specialty Oncology
Date 2015 Apr 23
PMID 25900242
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Medullary thyroid carcinoma (MTC) is a neuroendocrine cancer of thyroid C-cells, for which few treatment options are available. We have recently reported a role for cyclin-dependent kinase 5 (CDK5) in MTC pathogenesis. We have generated a mouse model, in which MTC proliferation is induced upon conditional overexpression of the CDK5 activator, p25, in C-cells, and arrested by interrupting p25 overexpression. Here, we identify genes and proteins that are differentially expressed in proliferating versus arrested benign mouse MTC. We find that downstream target genes of the tumor suppressor, retinoblastoma protein, including genes encoding cell cycle regulators such as CDKs, cyclins and CDK inhibitors, are significantly upregulated in malignant mouse tumors in a CDK5-dependent manner. Reducing CDK5 activity in human MTC cells down-regulated these cell cycle regulators suggesting that CDK5 activity is critical for cell cycle progression and MTC proliferation. Finally, the same set of cell cycle proteins was consistently overexpressed in human sporadic MTC but not in hereditary MTC. Together these findings suggest that aberrant CDK5 activity precedes cell cycle initiation and thus may function as a tumor-promoting factor facilitating cell cycle protein expression in MTC. Targeting aberrant CDK5 or its downstream effectors may be a strategy to halt MTC tumorigenesis.

Citing Articles

Looking at Thyroid Cancer from the Tumor-Suppressor Genes Point of View.

Rajabi S, Alix-Panabieres C, Alaei A, Abooshahab R, Shakib H, Ashrafi M Cancers (Basel). 2022; 14(10).

PMID: 35626065 PMC: 9139614. DOI: 10.3390/cancers14102461.


Selective Antitumor Activity of Datelliptium toward Medullary Thyroid Carcinoma by Downregulating RET Transcriptional Activity.

Alqahtani T, Alswied A, Sun D Cancers (Basel). 2021; 13(13).

PMID: 34209165 PMC: 8267783. DOI: 10.3390/cancers13133288.


Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review.

Lukasik P, Zaluski M, Gutowska I Int J Mol Sci. 2021; 22(6).

PMID: 33805800 PMC: 7998717. DOI: 10.3390/ijms22062935.


Phosphoprotein-based biomarkers as predictors for cancer therapy.

Carter A, Tan C, Pozo K, Telange R, Molinaro R, Guo A Proc Natl Acad Sci U S A. 2020; 117(31):18401-18411.

PMID: 32690709 PMC: 7414192. DOI: 10.1073/pnas.2010103117.


Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapy.

Si Y, Kim S, Ou J, Lu Y, Ernst P, Chen K Cancer Gene Ther. 2020; 28(7-8):799-812.

PMID: 32684623 PMC: 7854894. DOI: 10.1038/s41417-020-0196-5.


References
1.
Bracken A, Ciro M, Cocito A, Helin K . E2F target genes: unraveling the biology. Trends Biochem Sci. 2004; 29(8):409-17. DOI: 10.1016/j.tibs.2004.06.006. View

2.
Pfragner R, Hofler H, Behmel A, Ingolic E, WALSER V . Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res. 1990; 50(13):4160-6. View

3.
Mulligan L, Kwok J, Healey C, Elsdon M, Eng C, Gardner E . Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993; 363(6428):458-60. DOI: 10.1038/363458a0. View

4.
Hofstra R, Landsvater R, Ceccherini I, Stulp R, STELWAGEN T, Luo Y . A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature. 1994; 367(6461):375-6. DOI: 10.1038/367375a0. View

5.
Goretzki P, Gorelov V, Dotzenrath C, Witte J, Roeher H . A frequent mutation/polymorphism in tumor suppressor gene INK4B (MTS-2) in papillary and medullary thyroid cancer. Surgery. 1996; 120(6):1081-8. DOI: 10.1016/s0039-6060(96)80059-6. View